The COMPASSION Study

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Not applicable

Age range

18 years - Not specified

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

200 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Patient of any gender with unresectable locally advanced or metastatic breast cancer
• Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \</= 1 week before enrollment
• Ability to conduct video or phone check-ins, even if assistance required.
• Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
• Hospice setting is within Massachusetts
• Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
• Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment

Exclusion Criteria:

• Unable to provide verbal consent
• Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
• Hospice setting outside of Massachusetts
• Individuals who are under the age of 18, as this is not a project focused on pediatric patients.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not randomized

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Dana-Farber Cancer Institute

Study start

Sep 1, 2024 Actual

Primary completion

Oct 1, 2028 Estimated

Study completion

Mar 1, 2029 Estimated

First posted

Jul 18, 2024 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts